Ultrasound Can ID Breast Cancer Patients Who Need Lymph Nodes Removed
The investigators found that repeating ultrasound after chemotherapy could help to determine whether surgeons should remove only a few lymph nodes and test them for cancer, sparing patients whose sentinel nodes are cancer-free the removal of all nodes in the armpit, or take out all of the nodes.
“Our goal here is really to try to get away from, ‘Every patient with breast cancer needs these drugs, and this amount of chemotherapy and this surgery,’ and instead to personalise surgical treatment based on how the patient responds to chemotherapy,” said the study's lead author Judy C. Boughey, MD, a breast surgeon at Mayo Clinic in Rochester, NY.
In the past, when breast cancer was discovered to have spread to the lymph nodes under the arm, surgeons routinely removed all of them. However, taking out all of those lymph nodes may cause lymphoedema and limit the arm’s range of motion.
These days many breast cancer patients receive chemotherapy before surgery. Given improvements in chemotherapy drugs and increasing use of targeted therapy, surgeons are seeing more women whose cancer is eradicated from the lymph nodes by the time they reach the operating room, Dr. Boughey noted.
“That’s one of the really nice things about giving chemotherapy up front: It allows us to be less invasive with surgery, both in terms of breast surgery and lymph node surgery, and to tailor treatment based on response to chemotherapy,” she said.
Avoiding complete underarm lymph node removal when possible means fewer women will experience the complications that can result from that surgery, and avoiding those side effects should also save healthcare costs, the doctor added.
Most patients with lymph node-positive breast cancer receive radiation treatment after surgery. A new study is under way for men and women with breast cancer whose underarm lymph nodes are still positive for cancer after chemotherapy. The goal is to evaluate which is more effective: removing all of those nodes, or leaving the nodes and treating them with radiation, Dr. Boughey explained.
The current research was supported by National Cancer Institute grants U10 CA76001 to the American College of Surgeons Oncology Group, CA31946 to the Alliance for Clinical Trials in Oncology and CA33601 to the Alliance Statistics and Data Center.
Source: Mayo Clinic
Image Credit: Wikimedia Commons
Published on : Mon, 2 Feb 2015
With its customer driven design, amazing usability and freedom of movement, Agfa's DR 100s offers your facility a new force in mobile imaging. Combining a remarkably narrow width and light weight with a powerful generator and imaging processing, it puts...
The iViz is a lightweight Point Of Care (POC) ultrasound solution, specifically designed for emerging sub-segments where there is need for a highly accessible and mobile solution that is capable throughout key areas of the patient care path. The iViz...
About the Affirm® breast biopsy guidance system Our passion to offer innovative interventional tools that advance breast health fueled the development of the Affirm breast biopsy guidance system. This simple add-on to any Hologic 3D Mammography™-capable...
Introducing a new chapter in ultrasound visualization technology. X-Porte was developed from the ground up to incorporate a breakthrough, proprietary beam-forming technology: XDI (Extreme Definition Imaging). This signal analysis algorithm shapes...